# A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

Study · id `cardio:ct-nct06340854` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06340854](<https://clinicaltrials.gov/study/NCT06340854>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06340854

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 412 participants.

## Technical summary

Registry record NCT06340854. Randomized; no masking; primary purpose treatment. Start 2024-04-19 (actual); primary completion 2025-05-08 (actual). Results posted on 2026-07-02.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 412 participants (enrolled count; ClinicalTrials.gov record NCT06340854, source copy `cardio:ctgov-nct06340854-2026-08-11`, retrieved 2026-10-26)
- Started: 2024-04-19 (actual) (ClinicalTrials.gov record NCT06340854, source copy `cardio:ctgov-nct06340854-2026-08-11`, retrieved 2026-10-26)
- Primary completion: 2025-05-08 (actual) (ClinicalTrials.gov record NCT06340854, source copy `cardio:ctgov-nct06340854-2026-08-11`, retrieved 2026-10-26)
- Completion: 2025-06-13 (actual) (ClinicalTrials.gov record NCT06340854, source copy `cardio:ctgov-nct06340854-2026-08-11`, retrieved 2026-10-26)
- Results first posted: 2026-07-02 (ClinicalTrials.gov record NCT06340854, source copy `cardio:ctgov-nct06340854-2026-08-11`, retrieved 2026-10-26)
- Countries: United States; Bulgaria; Germany; India; Japan; Poland; Puerto Rico; South Africa; Spain (ClinicalTrials.gov record NCT06340854, source copy `cardio:ctgov-nct06340854-2026-08-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06340854-2026-08-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
- Condition: Diabetes, Type 2
- Intervention (Drug): Insulin icodec
- Intervention (Drug): Insulin glargine
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Simplified Switching to Once-Weekly Insulin Icodec Without an Initial One-Time Additional Dose Versus Once-Daily Insulin Glargine U100 in Basal Insulin-Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial (`cardio:pubmed-42168822`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2e0aca47f20c41f5f1fdebf3fd3b90f87cdc7522458213e634c5ab76e4217a3a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
